The share price of Edinburgh, UK-based NuCana plc rose sharply on NASDAQ on Oct. 2, the day the biotech closed its initial public offering that raised a hefty $114m (£75m).
The Scottish biopharmaceutical company, previously known as NuCana BioMed Ltd., expects to use the proceeds of the IPO to "reach key milestones" in its clinical-stage anticancer development plans and in associated CMC and manufacturing activities, NuCana CEO Hugh Griffith said